Such findings not only reveal the function of STAT3 in the regulation of the β-TrCP/β-catenin/NF-κB axis, but also highlight the need to further investigate CIB-6 as a new therapeutic strategy for the treatment of HCC. Here, STAT3 is linked to hepatocellular carcinoma.